Test-retest reliability and validity of movement-evoked pain in patients with knee osteoarthritis: a methodological study protocol Authors: Liming Jiang, Dongfu Liu, Ramakrishnan Mani, Roy TH Cheung, Yuelong Cao, Ru Wang, Zhihui Lu, Sizhong Wang Published: 2026 ABSTRACT AbstractIntroductionPain experienced during functional activities, referred to as movement-evoked pain (MEP), is a common and disabling symptom in individuals with knee osteoarthritis (KOA). Unlike pain at rest, MEP may better reflect the real-life burden of KOA and is increasingly recognised as a core outcome in musculoskeletal pain trials. However, its clinical utility remains limited by a lack of evidence on its measurement properties. This study aims to evaluate the test-retest reliability and validity of MEP assessments during functional tasks in individuals with KOA.Methods and analysisThis study includes two components: (1) a test-retest reliability assessment conducted over two sessions separated by approximately 7 days and (2) a cross-sectional analysis of convergent validity. We will recruit 62 participants with symptomatic KOA from the local communities. MEP will be assessed using an 11-point Numeric Rating Scale during five standardised functional tasks: 30-Second Chair Stand Test, One-Step Stair Climb Test, 40m Fast-Paced Walk Test, Timed Up and Go Test and Six-Minute Walk Test. Test-retest reliability will be evaluated using intraclass correlation coefficients (ICC3,1). Convergent validity will be assessed separately for each functional task by calculating correlation coefficients between MEP ratings and the pain subscale of the Knee injury and Osteoarthritis Outcome Score.Ethics and disseminationThis study was approved by the Ethics Committee from Shanghai University of Sport (Ref: 102772025RT193). The study protocol was registered on the Open Science Framework (10.17605/OSF.IO/B9N7G). The findings will be disseminated through presentations at national and international scientific conferences and submitted for publication in a peer-reviewed journal.Keywords: Aging, Chronic Pain, Rehabilitation medicine STRENGTHS AND LIMITATIONS OF THIS STUDY The methodological design adheres to Guidelines for Reporting Reliability and Agreement Studies (GRRAS) guidelines and incorporates standardised protocols for functional task performance and pain rating to ensure methodological rigour. The methodological design adheres to Guidelines for Reporting Reliability and Agreement Studies (GRRAS) guidelines and incorporates standardised protocols for functional task performance and pain rating to ensure methodological rigour. Real-time pain ratings using an 11-point Numeric Rating Scale (NRS) immediately post-task ensure that pain is captured in the context of meaningful movement, improving ecological validity. Real-time pain ratings using an 11-point Numeric Rating Scale (NRS) immediately post-task ensure that pain is captured in the context of meaningful movement, improving ecological validity. Focusing on five Osteoarthritis Research Society International (OARSI)-recommended functional tasks may limit the generalisability of findings to other functional activities not included in the protocol. Focusing on five Osteoarthritis Research Society International (OARSI)-recommended functional tasks may limit the generalisability of findings to other functional activities not included in the protocol. All assessments will be conducted by a single physiotherapist, which may introduce rater bias and precludes evaluation of inter-rater reliability. All assessments will be conducted by a single physiotherapist, which may introduce rater bias and precludes evaluation of inter-rater reliability. Introduction Knee osteoarthritis (KOA) is one of the most prevalent musculoskeletal conditions globally, leading to pain, reduced mobility and functional impairment in middle-aged and older adults.1 Pain is the most common and disabling symptom in KOA, yet its assessment remains complex due to its multifaceted and dynamic nature.1 2 Traditionally, pain intensity has been assessed at rest using self-report tools such as the Numeric Rating Scale (NRS) or the Visual Analogue Scale.3 However, these measures often fail to capture the variability and functional relevance of pain experienced during daily activities. Movement-evoked pain (MEP) refers to the intensity of pain that is triggered or worsened by physical movement or functional tasks.4 Unlike resting pain, MEP has been shown to be more closely associated with physical function, disability and real-life limitations in people with chronic musculoskeletal conditions.4 5 In recognition of its clinical relevance, functional pain or MEP has been recommended as a core outcome domain in chronic pain trials by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and other international working groups.6 However, standardised approaches for assessing MEP in individuals with KOA are limited, and psychometric properties such as test-retest reliability and validity remain insufficiently established.4 7 8 The Osteoarthritis Research Society International (OARSI) recommends a core set of performance-based tests for evaluating physical function in individuals with KOA, including the 30-Second Chair Stand Test (30sCST), Stair Climb Test (SCT), 40m Fast-Paced Walk Test (40mFPWT), Timed Up and Go Test (TUG) and Six-Minute Walk Test (6MWT).9 These tests impose standardised mechanical loads on the knee joint, providing an opportunity to evaluate MEP during tasks representative of common daily activities. These tasks involve joint loading, quadriceps activation and rapid shifts in joint position, all of which can provoke or exacerbate pain in affected individuals with KOA.9 Although these tasks are widely used in research and rehabilitation, evidence is lacking on whether MEP measured during these tasks accurately captures the lived pain experience of people with KOA. Establishing construct validity is essential if MEP is to be adopted as a core outcome in clinical trials; without it, the clinical and research value of MEP remains uncertain. MEP intensity is likely influenced by both peripheral and central sensitisation.4 10 11 Psychological factors such as pain catastrophising and fear-avoidance beliefs are also weakly to moderately associated with MEP in people with musculoskeletal pain, including KOA.12 Importantly, MEP ratings may help identify individuals with heightened pain sensitivity, which has been linked to central sensitisation and poorer clinical outcomes.13 Pain responses to movement may fluctuate across days due to factors such as inflammation, fatigue, mood, sleep disturbances and central sensitisation.14 15 Therefore, assessing between-day test-retest reliability of MEP is essential before interpreting longitudinal changes or treatment effects.16 17 Determining the minimal detectable change (MDC) further enhances interpretability by quantifying the smallest change that can be considered beyond measurement error.18 Objectives To evaluate the test-retest reliability of MEP intensity ratings using the five OARSI-recommended functional performance tasks in patients’ KOA. To evaluate the test-retest reliability of MEP intensity ratings using the five OARSI-recommended functional performance tasks in patients’ KOA. To examine the convergent validity of MEP ratings in this population. To examine the convergent validity of MEP ratings in this population. Methods Study design This study will use a prospective observational design with a between-day test-retest reliability component and a cross-sectional validity assessment. A repeated-measures test-retest reliability study with two testing sessions separated by approximately 7 days.19 We will report this study as per the Guidelines for Reporting Reliability and Agreement Studies (GRRAS).20 The study was approved by the Ethics Committee of Shanghai University of Sport (Ethics number: 102772025RT193) and registered on the Open Science Framework (Registration DOI: 10.17605/OSF.IO/B9N7G). All participants will sign informed consent forms before participating. We will recruit participants from the local communities through advertisements on social media (eg, WeChat). All participants will be screened by a rehabilitation doctor with an expertise in musculoskeletal conditions. We will recruit participants with symptomatic KOA. The specific inclusion and exclusion criteria are detailed below. Inclusion criteria Participants must meet all of the following criteria: Aged 50 years or older. Aged 50 years or older. Persistent knee pain for ≥3 months. Persistent knee pain for ≥3 months. The diagnosis of KOA will be based on the criteria established by the American College of Rheumatology (ACR) criteria which include the presence of knee pain accompanied by at least three of the following clinical features: age 50 years or older, morning stiffness lasting less than 30 min, crepitus, bony tenderness, bony enlargement and absence of palpable warmth.21 The diagnosis of KOA will be based on the criteria established by the American College of Rheumatology (ACR) criteria which include the presence of knee pain accompanied by at least three of the following clinical features: age 50 years or older, morning stiffness lasting less than 30 min, crepitus, bony tenderness, bony enlargement and absence of palpable warmth.21 Knee symptoms that are either unilateral or bilateral, with one side being more severe and designated as the study knee. Knee symptoms that are either unilateral or bilateral, with one side being more severe and designated as the study knee. Being able to ambulate independently in the community. Being able to ambulate independently in the community. Being able to provide informed consent and willing to complete the movement tasks. Being able to provide informed consent and willing to complete the movement tasks. Exclusion criteria Participants will be excluded if any of the following apply: Unstable angina or myocardial infarction within the 3 months. Unstable angina or myocardial infarction within the 3 months. Resting heart rate above 120 beats per minute, systolic blood pressure above 180 mm Hg or diastolic pressure above 100 mm Hg. Resting heart rate above 120 beats per minute, systolic blood pressure above 180 mm Hg or diastolic pressure above 100 mm Hg. Acute chronic obstructive pulmonary disease or other acute lung disorders. Acute chronic obstructive pulmonary disease or other acute lung disorders. Clinically significant cardiac arrhythmias (eg, atrial fibrillation). Clinically significant cardiac arrhythmias (eg, atrial fibrillation). Neurological conditions (eg, stroke, multiple sclerosis, epilepsy, brain tumour, traumatic brain injury or spinal cord injuries). Neurological conditions (eg, stroke, multiple sclerosis, epilepsy, brain tumour, traumatic brain injury or spinal cord injuries). Musculoskeletal conditions affecting mobility: hip osteoarthritis, low back pain, lumbar radiculopathy/sciatica or lumbar canal stenosis. Musculoskeletal conditions affecting mobility: hip osteoarthritis, low back pain, lumbar radiculopathy/sciatica or lumbar canal stenosis. Sensory loss in the legs and feet. Sensory loss in the legs and feet. Vascular conditions in the legs (eg, peripheral arterial disease, venous disorders). Vascular conditions in the legs (eg, peripheral arterial disease, venous disorders). Recent knee surgery in the past 6 months. Recent knee surgery in the past 6 months. Previous hip or knee replacement surgery. Previous hip or knee replacement surgery. Fractures or dislocations of lower limb or pelvis in the past 6 months. Fractures or dislocations of lower limb or pelvis in the past 6 months. Intra-articular injection for KOA within the last 3 months. Intra-articular injection for KOA within the last 3 months. History of cancer or currently undergoing cancer treatment. History of cancer or currently undergoing cancer treatment. Use of analgesic medication within a week prior to testing. Use of analgesic medication within a week prior to testing. Trial sites We will conduct this study at local communities in Shanghai, China. Experimental procedure We will collect demographic information and patients’ self-reported questionnaires during the initial visit. Following these assessments, we will assess MEP for each participant using five tasks. The order of these five tasks will be randomised for each participant using the online research randomiser tool (randomizer.org), which will generate a unique sequence corresponding to the task numbers. During the second visit, we will assess MEP using the same tasks in the same order as the initial assessment. The test-retest interval will be set at approximately 7 days as recommended by Dobson et al.19 The experimental procedure of test-retest of MEP using different functional performance tasks is presented in figure 1. Test-retest protocol for movement-evoked pain assessment across different functional performance tasks. The order of tasks in the initial assessment will be randomised and the second assessment will follow the same as the initial assessment. Demographic information We will collect demographic information, including sex, age, weight, height, body mass index, education level, employment, dominant foot, painful knee, duration of knee pain, current medication or treatment for KOA. Self-reported questionnaires We will collect seven patients’ self-reported questionnaires in Chinese version, including (1) Knee injury and Osteoarthritis Outcome Score (KOOS);22 (2) knee osteoarthritis fears and beliefs questionnaire (KOFBeQ);23 (3) Pain Catastrophising Scale (PCS);24 (4) Depression, Anxiety, Stress Scale-21 (DASS-21);25 (5) intermittent and constant osteoarthritis pain (ICOAP)26 and (6) Pain Self-Efficacy Short Form.27 We will measure (7) sensitisation using the central sensitisation inventory (CSI) questionnaire.28 The detailed description of these questionnaires is presented in table 1. Table 1Baseline patient-reported outcome measures, corresponding questionnaires, domains assessed and scoring detailsBaseline assessmentQuestionnaireDescriptionSymptom and functionKnee injury and Osteoarthritis Outcome Score (KOOS)The KOOS is a 42-item, knee-specific self-reported questionnaire with five subscales: pain (9 items), symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items) and knee-related quality of life (4 items). Each item is scored from 0 (no problems) to 4 (extreme problems). Scores are transformed to a 0–100 scale, with 0 indicating extreme knee problems and 100 indicating no problems.Fears and beliefs related to knee osteoarthritisKnee Osteoarthritis Fears and Beliefs Questionnaire (KOFBeQ)The KOFBeQ is a validated 11-item self-report questionnaire with subscales: daily living activities (3 items), physicians (4 items), disease (2 items) and sports and leisure activities (2 items). Each item is scored from 0 (totally disagree) to 9 (totally agree). The total score ranges from 0 to 99, with higher scores indicating greater levels of fear-avoidance beliefs.Pain-related catastrophisingPain catastrophising scale (PCS)The PCS has 13 items covering three domains: rumination (5 items), magnification (3 items) and helplessness (5 items). Each item is scored from 0 (not at all) to 4 (all the time). Higher PCS scores indicate higher levels of pain catastrophising.Depression, anxiety and stressDepression, Anxiety, Stress Scale-21 (DASS-21)The DASS-21 is a shortened version of the original DASS-42 and consists of 21 items across three subscales: depression (7 items), anxiety (7 items) and stress (7 items). Each item is scored from 0 (did not apply to me at all) to 3 (applied to me very much or most of the time). Subscale scores are summed and then multiplied by 2 to obtain the final scores (range: 0–42 per subscale). Higher scores indicate greater psychological distress.Intensity and the qualitative experience of constant and intermittent painIntermittent and constant osteoarthritis pain (ICOAP)The ICOAP consists of 11 items divided into two subscales: Constant pain (5 items) and Intermittent pain (6 items). Each item is scored from 0 (not at all) to 4 (extremely). Subscale scores are summed and transformed to a 0–100 scale. Higher scores indicate more severe pain and greater impact on quality of life.Self-efficacyPain self-efficacy questionnaire−2 items (PSEQ-2)The PSEQ-2 is a brief measure derived from the original 10-item PSEQ, consisting of items 5 and 9. Each item is scored from 0 (not at all confident) to 6 (completely confident). Total scores range from 0 to 12, with higher scores indicating stronger pain-related self-efficacy.Central sensitisationCentral sensitisation inventory-9 items (CSI-9)The CSI-9 is a validated short-form tool for assessing symptoms of central sensitisation. It consists of nine items scored from 0 (never) to 4 (always), yielding a total score of 0–36. Higher scores reflect greater symptom burden associated with central sensitisation (eg, sensitivity to touch, fatigue, poor sleep, concentration difficulties). Baseline patient-reported outcome measures, corresponding questionnaires, domains assessed and scoring details While the KOOS pain subscale will serve as the primary reference for convergent validity, the remaining questionnaires are included for baseline cohort descriptive profiling and exploratory secondary analyses. These measures capture psychological, behavioural and central sensitisation constructs that are known to modulate pain perception during movement. Collecting these data will enable exploratory analyses to identify factors that may explain interindividual variability in MEP ratings and inform future mechanistic or intervention studies. Movement-evoked pain We selected five functional performance tasks that impose controlled and repeatable loading on the knee joint: 30sCST, One-Step SCT, 40mFPWT, TUG and 6MWT. These tasks are recommended by the OARSI and Outcome Measures in Rheumatology and are validated performance-based measures widely used in individuals with KOA and are designed to replicate typical weight-bearing activities known to provoke nociceptive responses.9 We selected these tasks based on their ability to replicate daily activities and their proven sensitivity to functional limitations and pain in individuals with KOA. Importantly, this protocol focuses exclusively on validating MEP as a pain intensity construct and will not record functional performance metrics (eg, completion time, distance or repetitions). Pain intensity and functional performance represent distinct clinical domains influenced by different physiological, biomechanical and psychological factors. By isolating MEP ratings from performance outcomes, we ensure that reliability and validity estimates specifically reflect the pain construct itself, avoiding confounding from multidimensional performance determinants. This approach aligns with IMMPACT and OARSI recommendations to evaluate pain intensity and physical function as separate, complementary outcome domains.6 29 30 MEP will be assessed using an 11-point NRS, where 0 represents ‘no pain’ and 10 represents ‘worst imaginable pain’. Participants will be instructed to rate the level of worst pain they experience during the task, just immediately after completing each task or trial.4 All five functional movement tasks will be administered by a single physiotherapist with more than 5 years of experience in clinical assessment. Prior to formal testing, a practice trial of each task will be conducted to ensure correct technique and participant understanding. Detailed instructions for assessing MEP are provided in online supplemental file 1. 30s Chair Stand Test To assess MEP during the 30sCST, participants will sit on a standard armless chair (seat height: 44 cm) with their feet flat on the floor and arms folded across the chest. They will be instructed to repeatedly rise to a fully upright position and return to sitting for 30 s. Immediately after completing the test, participants will rate their worst pain experienced during the task using an 11-point NRS. 40m Fast-Paced Walk Test To assess MEP during the 40mFPWT, participants will be instructed to walk as quickly as possible, without running, along a marked 10 m walkway, turning at each end until they have completed four lengths (40 m in total). Immediately after completing the test, participants will rate the worst pain experienced during the task using an 11-point NRS. One-Step Stair Climb Test For the stair task, participants will perform five consecutive repetitions of stepping up onto and down from a single standardised step (step height: 20 cm) as quickly as possible. Each repetition will involve stepping up with the affected leg, followed by stepping down with the same leg. Immediately after completing the fifth repetition, participants will rate the worst pain experienced during the task using an 11-point NRS. Timed Up and Go Test To assess MEP during the TUG, participants will start seated in a standard armless chair (seat height: 43 cm) with their back against the backrest and feet flat on the floor. On the command ‘go’, they will rise from the chair, walk 3 m at a comfortable but brisk pace, turn around, return to the chair and sit down. Immediately after completing the test, participants will rate the worst pain experienced during the task using an 11-point NRS. Six-minute walk test For the 6MWT, participants will be instructed to cover as much distance as possible in 6 min along a rectangular pathway. The 6MWT has previously established reliability and validity among older adults. Patients will be asked to rate their pain using the 11-point NRS after each minute of walking, for a total of six pain ratings. An index score of pain during walking was created by averaging patients’ six pain scores. Sample size calculation The sample size for this study was determined based on the requirements for both test-retest reliability and construct validity analyses. For the test-retest reliability component, an intraclass correlation coefficient (ICC) of 0.80 was assumed, with a minimum acceptable ICC of 0.60, a significance level of 0.05 and 80% power. Using established methods,31 32 the estimated minimum sample size was 49 participants. To allow for approximately 20% dropout, the final sample size is 62 participants. Sample size calculation for reliability component was using online calculator: https://wnarifin.github.io/ssc/ssicc.html. For convergent validity, we assumed a moderate correlation (r=0.4) between MEP and KOOS pain subscale, a sample of 47 would provide 80% power at α=0.05. Sample size calculation for validity component was performed using G*Power V.3.1. Therefore, a sample of 62 is sufficient to meet both objectives. Statistical analysis We will use descriptive statistics to summarise participant characteristics. We will report the means and SD of MEP under five functional tasks. We will use intraclass correlation coefficient (ICC3,1), SE of measurement (SEM), 95% minimal detectable change (MDC95%) and Bland-Altman plot to assess the test-retest reliability of the measures.33 Specifically, we will estimate the ICC values and their 95% CI using a two-way mixed-effects model for single measurements with absolute agreement. We will interpret reliability magnitude according to established benchmarks: poor (ICC <0.5), moderate (0.5–0.75), good (0.75–0.9) and excellent (ICC >0.9).18 To quantify absolute reliability, we will derive the SEM from the square root of the mean square error term generated by a repeated-measures analysis of variance, and then calculate MDC95% as SEM×1.96×√2. Finally, we will construct Bland-Altman plots to visually inspect agreement between sessions, computing the mean difference and 95% limits of agreement (mean difference±1.96×SD) to identify any systematic bias. We will calculate convergent validity separately for each functional task by assessing correlations between task-specific MEP rating and KOOS pain subscale. Pearson’s correlation coefficient will be used if both variables meet assumptions of normality (assessed via Shapiro-Wilk test and visual inspection of histograms/Q-Q plots); otherwise, Spearman’s rank correlation (ρ) will be reported. Correlation coefficients with 95% CIs will be interpreted according to standard thresholds: small (|r|<0.3), medium (0.3–0.5), large (0.5–1).18 All statistical analyses will be performed using STATA software. Discussion This study aims to address this gap by evaluating the between-day test-retest reliability and validity of MEP ratings during five commonly used functional tasks: 30sCST, One-Step SCT, 40mFPWT, TUG and 6MWT. These tasks simulate everyday activities, are simple to administer and provide ecologically valid scenarios for pain assessment. To our knowledge, this will be the first study to systematically investigate the reliability and validity of MEP ratings during these functional tasks in this population. The test-retest component of this study is designed to determine the consistency of MEP ratings over time under stable clinical conditions. Because MEP may fluctuate between days due to biological and psychological factors, such as inflammation, mood, fatigue and central sensitisation,14 15 it is critical to establish its reproducibility before using it as a longitudinal outcome. In addition to ICC, we will calculate the SEM and MDC to quantify measurement error and define the threshold beyond which observed changes can be interpreted as real.18 These metrics will be valuable not only for researchers conducting clinical trials but also for clinicians monitoring patient progress during rehabilitation. The validity component of the study focuses on establishing convergent validity by examining associations between MEP and established patient-reported outcomes, including KOOS pain subscale. If significant correlations are found, this would support MEP as a clinically meaningful indicator of pain-related disability and functional limitation, aligning with prior evidence that MEP better reflects functional impairments than pain at rest.4 5 Furthermore, analysing MEP separately for each of the five functional tasks preserves their distinct biomechanical demands (eg, high knee loading during stair climbing vs repetitive low-load ambulation during walking), allowing for a more precise interpretation of how pain manifests across different movement contexts. Such knowledge could ultimately inform the tailoring of pain management and rehabilitation strategies. The methodological design adheres to recommended guidelines for reliability studies (GRRAS) and incorporates standardised protocols for task performance and pain rating.20 By employing standardised task protocols and real-time pain ratings on an 11-point NRS, this study will enhance ecological validity and ensure that pain is captured in the context of meaningful movement. The clinical relevance of MEP will be evaluated through its convergent validity with the KOOS pain subscale, which explicitly assesses pain severity during specific daily activities. Because KOOS pain items are functionally contextualised, a significant correlation would demonstrate that MEP ratings reflect meaningful activity-related burden rather than isolated symptom reporting. Nevertheless, some limitations must be acknowledged. First, focusing on the five OARSI-recommended functional performance tasks may limit the generalisability of the findings to other functional activities. Second, all assessments will be conducted by a single rater, which may introduce rater bias and does not allow evaluation of inter-rater reliability. Finally, pain ratings are inherently subjective and may be influenced by factors such as mood, fatigue or daily symptom fluctuations, which could introduce variability beyond the measurement itself. While future studies may benefit from concurrently analysing MEP and functional performance outcomes, this protocol prioritises establishing MEP’s psychometric foundation as an independent measure. Validating MEP separately ensures it can be reliably adopted as a pain-specific endpoint in trials. Subsequent research can integrate MEP with performance metrics to explore pain-behaviour interactions, activity pacing and clinically meaningful response thresholds in rehabilitation settings. In summary, this study is expected to provide foundational evidence on the reliability and validity of MEP as a clinical outcome measure in individuals with KOA. Establishing MEP as a psychometrically robust measure could contribute significantly to both clinical practice and research. Clinically, MEP may offer a more sensitive tool to monitor treatment response and guide rehabilitation interventions targeting function-related pain. From a research perspective, incorporating validated MEP assessments in trials may improve the detection of meaningful changes in patient-centred outcomes. Ultimately, this study aims to promote the use of MEP as a core outcome domain, in line with recommendations from IMMPACT and other international pain research groups, to advance the quality and relevance of KOA assessment and care. This study will contribute to the growing literature on functional pain assessment and provide empirical support for the use of MEP as a reliable outcome measure in patients with KOA. Supplementary material Footnotes Funding: This study was sponsored by Shanghai Pujiang Program (25PJC075) and Start-up Research Grant from Shanghai University of Sport (Grant No. A1-2G01-25-0010-11). Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-116380). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. References Supplementary Materials